Quarterly report [Sections 13 or 15(d)]

SEGMENT INFORMATION

v3.25.0.1
SEGMENT INFORMATION
 3 Months Ended
Jan. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) Cancer Vaccines, (ii) CAR-T Therapeutics, and (iii) Other. The following represents selected financial information for our segments for the three months ended January 31, 2025 and 2024 and as of January 31, 2025 and October 31, 2024 (in thousands):

  

    2025     2024  
    For the Three Months Ended
January 31,		  
    2025     2024  
Net loss:                
Cancer Vaccines   $ (2,018 )   $ (1,756 )
CAR-T Therapeutics     (1,177 )     (1,525 )
Other     (18 )     (9 )
Total   $ (3,213 )   $ (3,290 )
                 
Total operating costs and expenses   $ 3,386     $ 3,609  
Less non-cash stock-based compensation     (1,055 )     (1,260 )
Operating costs and expenses excluding non-cash stock-based compensation   $ 2,331     $ 2,349  
Operating costs and expenses excluding non-cash stock-based compensation expense:                
Cancer Vaccines   $ 1,467     $ 1,213  
CAR-T Therapeutics     848       1,128  
Other     16       8  
Total   $ 2,331     $ 2,349  

  

    January 31,
2025		     October 31,
2024		  
Total assets:                
Cancer Vaccines   $ 11,863     $ 12,917  
CAR-T Therapeutics     6,885       8,535  
Other     158       139  
Total   $ 18,906     $ 21,591  

 

Operating costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.